By Dane Bowler : In this series of articles, we take a dive into REIT valuations across the various sectors to determine where there is still opportunity for outperformance. Part 1 covered healthcare , part 2 covered industrials and the focus of this article will be on residential REITs. ...
Started with Buys are Mid - America Apartment Communities ( MAA -0.1% ), and Camden Property Trust ( CPT ), and initiated at Neutral are Home Properties ( HME -0.4% ), and UDR ( UDR ). Post your comment!
The European Medicines Agency accepts Cubist Pharmaceuticals' (NASDAQ: CBST ) Marketing Authorization Application for ceftolozane/tazobactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. The European Commission should announce its decision by
more than $900M after racking up big gains in the stocks this year. The biggest reductions were in Mid - America Apartment Communities ( MAA +0.3% ), AvalonBay ( AVB +0.8% ), and Equity Lifestyle Properties ( ELS +0.2% ), and
Residential (NYSE: EQR ) and AvalonBay (NYSE: AVB ) are at all-time highs, but their owners may want to mull the fast pace of building. Others of interest: ESS , PPS , UDR , AIV , CPT , HME , MAA , TSRE , AEC , IRET , APTS Post your comment!
Following discussions with European regulatory authorities, Insmed Corp. (NASDAQ: INSM ) plans to file a Marketing Authorization Application with the EMA for Arikayce (liposomal amikacin for inhalation) for the treatment of nontuberculous mycobacteria (NTM) lung infections in treatment refractory
Mid - America Apartment Communities , Inc. (NYSE: MAA ) Q2 2014 Earnings Conference Call July 31, 2014 10:00 AM ET Executives Tim Argo ..... ladies and gentlemen. And thank you for participating in the MAA Second Quarter 2014 Earnings Conference Call. At this time
Mid America Apartment (NYSE: MAA ): Q2 FFO of $1.18 misses by $0.07 . Revenue of $244.49M (+85.5% Y/Y) misses by $2.3M . Press Release Post your comment!
180 List of Outstanding Issues to Orexigen Therapeutics ( OREX -2.7% ) regarding its Marketing Authorization Application ( MAA ) for NB32 (naltrexone/bupropion), its investigational drug candidate for weight loss. Orexigen believes it addressed the
of $15M and another payment of $10M upon EMA approval. It will also be eligible for milestone payments and royalties on sales. The MAA for dalbavancin is currently under EMA review. A decision is expected in 1H 2015. Post your comment!